Toyobo Co., Ltd.

Japan Tobacco Inc.

Masafumi Inoue

Masayuki Haruta

Hiroshi Kawakami

Hiroshi Nakamura

Hisashi Shinkai

Yuji Matsuzaki

Motohide Satoh

Hisateru Aramaki

Hiroshi Yamamoto

Takuya Matsuo

Takashi Inaba

Takahiro Yamasaki

Hiroshi Yamanaka

Takahisa Motomura

Makoto Shiozaki

Ikuo Mitani

Koichi Suzawa

Satoru Noji

Shuichi Wamaki

Tomoya Miura

Kazunobu Yamataka

Takao Ito

Tsubasa Takeichi

Masaki Yamashita

Hirotsugu Ito

Yosuke Ogoshi

Yuichi Nakagawa

Katsuya Maeda

Nobutaka Yamaoka

Yoshinori Hara

Yasunori Hase

Akimi Hori

Takuya Machida

Takayuki Furukawa

Kazuhito Harada

Yukishige Ikemoto

Yasuyuki Kajimoto

The present invention aims to provide a heat-shrinkable polyester film roll having decreased generation of wrinkles or longitudinal shrink mark. The present invention provides a film roll of a heat shrinkable polyester film, wherein a polyester of the polyester film contains recycled raw material from a PET bottle and an acid component of the polyester comprises isophthalic acid, and the film roll satisfies a specific average value of a shrinkage, specific isophthalic acid ratio, and specific thickness unevenness.

Heat-shrinkable polyester-based film roll

A heat-shrinkable polyester film that has (1) a hot-water heat shrinkage of 40% or more in a main shrinkage direction of the film when immersed in hot water of 98° C. for 10 seconds; (2) a planar orientation coefficient of 0.035-0.070; (3) ethylene terephthalate as a main constituent component and 6-25 mol % diethylene glycol (DEG) constituent in 100 mol % of polyhydric alcohol in all the polyester resin constituting the film; (4) a maximum shrinkage stress of 2-17 MPa in the main shrinkage direction of the film when measured in hot air of 90° C.; and (5) a tensile elongation at break of 20% or more in a direction orthogonal to the main shrinkage direction after the film is aged in an atmosphere with an atmospheric temperature of 40° C. and a relative humidity of 85% for 28 days.

Heat-shrinkable polyester film

The invention provides a heat-shrinkable polyester film roll obtained by winding a heat-shrinkable polyester film on a paper tube with primary shrinkage in the longitudinal direction and a shrinkage rate of 40% or more, wherein the film has a winding length of 1000 to 30000 m, a width of 50 to 1500 mm, and a thickness of 5-30 μm, the thickness irregularity of the film roll in the width direction is 20% or less, the paper tube has an inner diameter of 3 inches with a 0.5 mm or less difference in clearance and a 1700 N/100 mm or more flat compressive strength in the width direction after the film is removed from the film roll, the mean value of the winding hardness of the surface layer part of the film roll in the width direction is 500-850, and the natural shrinkage rate in the longitudinal direction is 2.0% or less.

Film roll of heat-shrinkable polyester

The present invention provides a compound having a Pim-1 inhibitory activity. The present invention provides a compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a pharmaceutical use thereof, and the like. wherein each symbol is as defined in the description.

Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof

Provided is a heat-shrinkable polyester film which has heat shrinkage properties in a main shrinkage direction in the longitudinal direction, a small variation in shrinkage in the width direction, and less likely generated wrinkles and strains at the time of shrinkage finishing. The polyester film is prepared from a polyester raw material resin comprising 50 mol % or more of an ethylene terephthalate unit in 100 mol % of constituent units of a polyester, diol components selected from aliphatic, alicyclic, and aromatic diols, and an amorphous monomer component that is 2% or more in 100 mol % of either a polyhydric alcohol component or a polybasic carboxylic acid component in the whole polyester resin, wherein the polyester does not contain polybasic carboxylic acids of tribasic or more, and the polyester film is obtained by uniaxial drawing in the longitudinal direction.

Heat-shrinkable polyester film and package

A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

Production method for pyrazole-amide compound

The invention provides a heat-shrinkable polyester film, which has a main shrinkage direction in a longer direction, exhibits a higher shrinkage ratio in the main shrinkage direction, has small difference in shrinkage ratio at a high temperature and a low temperature so as not likely to generate wrinkles or the like when being used as a label, and exhibits small over-time decrease in shrinkage ratio at a low temperature. The heat-shrinkable polyester film has, as a main component, ethyleneterephthalate, and an amount of a diethyleneglycol (DEG) component is 10-25 mol % with respect to 100 mol % of a polyhydric alcohol component in all of polyester resin that composes the film.

Heat-shrinkable polyester film and packaging

The invention provides a heat-shrinkable polyester film which has sufficient heat shrinkage properties in the main shrinkage direction that is the longitudinal direction without containing a monomer component that can form an amorphous component in a large amount, and which has a low heat shrinkage and a low shrinkage stress in the width direction orthogonal to the main shrinkage direction. The film has a heat shrinkage of 15-50% in a main shrinkage direction of the film and 0-12% in a direction orthogonal to the main shrinkage direction of the film, when treated for 10 seconds in hot water of 90&#xb0; C., and a maximum shrinkage stress of 2-10 MPa in the main shrinkage direction of the film when measured under hot air of 90&#xb0; C. The film contains 7-30 mol % of a constituent unit derived from diethylene glycol in 100 mol % of the whole polyester resin component.

A heat-shrinkable polyester-based film is provided, which is heat-shrinkable in the longitudinal direction and which is freed from various problems, particularly curling-up or peeling in a bonded area. The heat-shrinkable polyester-based film is characterized by an A1/A2 (absorbance) ratio in the longitudinal direction, which is the main shrinking direction of the film, of 0.55 to 1, with an A1/A2 ratio in the width direction perpendicular to the main shrinking direction of 0.5 to 0.9, wherein A1 is the absorbance of the film at 1340 cmand A2 is the absorbance of the film at 1410 cmas determined by polarized ATR-FTIR spectroscopy, and a hot-water shrinkage of 35 to 60% in the longitudinal direction of the film and &#x2212;3 to 12% in the width direction of the film, wherein the hot-water shrinkage is determined by dipping the film in hot water at 90&#xb0; C. for 10 seconds.

Heat-shrinkable polyester film and packages

A heat-shrinkable polyester film comprising ethylene terephthalate as a main component, containing not less than 0 mol % and not more than 5 mol % of a monomer component capable of serving as an amorphous component relative to the total of a polyester resin component, and having a main shrinkage direction in a lengthwise direction, wherein the heat-shrinkable polyester film satisfies heat shrinkage characteristics of the width direction and the lengthwise direction and the molecular orientation angle difference which is a difference between a molecular orientation angle of an edge of one end in the width direction and a molecular orientation angle of an edge of the other end.

A compound of the following general formula [I]: wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.

Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor

A pharmaceutical agent having an anti-HIV action, particularly, a pharmaceutical agent having an integrase inhibitory action, is provided. The present invention relates to a quinolizinone compound represented by the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compounds can become a more effective anti-HIV agent. Since the compound has a high inhibitory activity specific for integrases, the compound can provide a safe pharmaceutical agent for human with a fewer side effects.

Growing community of inventors

Tsuruga, Japan

Masafumi Inoue